Morgan Stanley maintains Legend Biotech at Overweight, lowers price target to $43 from $49

Morgan Stanley kept its Overweight rating on Legend Biotech but cut its price target to $43 from $49, a 12.2% reduction. The new target suggests a 110.7% upside from the Nov 10 closing price of $20.41, according to the firm.

Original reporting
Published Nov 11, 2026, 5:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 5:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains Legend Biotech at Overweight, lowers price target to $43 from $49 — source image
Decision brief

The 30-second read

Med
01

Why it matters

Analyst target reductions can trigger short-term sell pressure, especially for low‑float stocks.

02

Market read

The downgrade provides a fresh data point for traders monitoring micro‑cap biotech equities.

03

What to watch

Potential pipeline milestones not reflected in the downgrade.

Relevance 7/10Novelty 6/10Timing: today

Background

Morgan Stanley's rating maintenance at Overweight with a lower price target reflects a shift in valuation expectations.

Market effects

Biotech sector may see modest downside as analyst cuts spread.

US biotech investors could adjust exposure.

Limited, primarily US micro‑cap focus.

Counterpoint

The target cut may be overly cautious if upcoming trial data is positive.

Key entities

  • Legend Biotech

    US‑listed biotech (ticker LGND) subject of the analyst downgrade.

  • Morgan Stanley

    Equity research firm issuing the price target change.

Related articles

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.

$LEGNMedAI 8/10

Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%

Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.

$LEGNHigh

Legend Biotech Corp (LEGN): Financial results for Q3 2026

Legend Biotech Corp (LEGN) furnished an SEC Form 6-K — earnings release. Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights • CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million • Half of CARTITUDE-2 Cohort A patients remained alive and progress